Latest Healthcare Policy Update | Budget 2026–27
In a major relief for cancer patients across India, the Union Budget 2026–27 has announced basic customs duty exemption on 17 critical, previously imported cancer drugs.
Though this is not a new drug approval, the move is expected to significantly improve affordability and availability of life-saving oncology treatments.
What Has Been Announced?
The Government of India has exempted 17 essential cancer medicines from Basic Customs Duty (BCD). This decision is aimed at:
- Reducing treatment costs
- Improving access to advanced oncology therapies
- Strengthening supply of imported critical drugs
Among the key drugs included are:
- Ribociclib
- Abemaciclib
- Venetoclax
These drugs are widely used in treating advanced and resistant forms of cancer, including breast cancer and blood cancers.
Why This Move Matters
Impact on Patients:
- Lower overall treatment cost
- Better access to targeted therapies
- Improved continuity of care
Impact on Healthcare System:
- Reduced dependency on high-cost imports
- Streamlined supply chain
- Support for critical oncology programs
Cancer treatment in India often requires long-term therapy, making cost a major burden. Customs duty exemption directly addresses affordability concerns.
Economic & Policy Significance
| Policy Decision | Expected Benefit |
| Customs duty exemption | Lower import cost |
| Inclusion of critical oncology drugs | Improved patient access |
| Budgetary healthcare focus | Strengthened public health support |
This step signals a stronger commitment to:
- Public health equity
- Oncology treatment access
- 🇮🇳 Strengthening India’s healthcare affordability
About the Included Drugs
- Ribociclib & Abemaciclib – Used in hormone receptor-positive breast cancer treatment.
- Venetoclax – Used in certain blood cancers like chronic lymphocytic leukemia (CLL).
These therapies are often essential for patients with resistant or advanced-stage cancers.
Final Takeaway
17 critical cancer drugs exempted from customs duty
Improved affordability and availability
Major relief for oncology patients
Strong healthcare-focused Budget 2026–27 initiative
While not a new drug approval, this policy change could have a direct and meaningful impact on thousands of cancer patients across the country.
Recommended Products
